Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2025 08:05 ET | Source: MannKind

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

MannKind Announces U.S. FDA Accepts for Review its sNDA of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in adults with CHF or CKD
November 11, 2025 16:05 ET | Source: MannKind

MannKind to Present at the Jefferies Global Healthcare Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that Michael Castagna, Chief Executive Officer, and Chris Prentiss,...
November 10, 2025 08:00 ET | Source: MannKind

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
November 06, 2025 09:00 ET | Source: MannKind

MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
November 05, 2025 08:00 ET | Source: MannKind

MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update

MANNKIND CORPORATION REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
October 29, 2025 16:05 ET | Source: MannKind

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its third quarter 2025 financial results will be released...
October 13, 2025 08:05 ET | Source: MannKind

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

MannKind Announces U.S. FDA Accepts for Review its sBLA for Inhaled Insulin in Children and Adolescents Aged 4-17
October 07, 2025 09:00 ET | Source: MannKind

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
September 29, 2025 06:05 ET | Source: MannKind

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

MannKind appoints Dr. Ajay Ahuja as EVP and Chief Medical Officer
August 27, 2025 16:05 ET | Source: MannKind

MannKind to Present at Upcoming Investor Conferences

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative...